Novo Nordisk’s 27% drop was market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said
Trending
- JUST IN: Powerful DNC Official Turns On Party, Ditches Democrats
- What to know about the 2025 NBA All-Star Game
- Top 8 Software Development Technologies to Consider in 2025
- House Erupts In Chaos As GOP Clashes Over Trump-Backed Spending Bill
- Presbyterian Pastor Supports Abortions Up to Birth
- PENNSYLVANIANS WANT BIDEN'S NAME OFF SCRANTON EXPRESSWAY AFTER JOE PARDONS 'KIDS FOR CASH' CRIMINAL
- China says US ‘playing with fire’ after latest military aid for Taiwan
- Two U.S. Navy Pilots Shot Down Over Red Sea In ‘Friendly Fire’ Incident
- CNN’s Ratings Collapse Continues As Viewership Plummets To All-Time Lows Among Key Demo
- Bob Dylan and the creative leap that transformed modern music